A randomized trial comparing interferon-alpha with XXXX for newly diagnosed @entity1860 in chronic phase.

@entity1 @entity1860 @entity3027 @entity1863
A multicenter randomized study was conducted to compare the effect of interferon-alpha ( @entity3027 ) with that of @entity1863 in newly diagnosed @entity1 with @entity1860 ( @entity1860 ) in chronic phase. From October 1988 to October 1991, 170 @entity1 were randomized to receive either @entity3027 or @entity1863 . Of 159 eligible @entity1 , 31 (38.8%) of 80 @entity1 in the @entity3027 group and 43 (54.4%) of 79 @entity1 in the @entity1863 group achieved complete hematologic remission, and 38.8% in the @entity3027 group and 43.0% in the @entity1863 group achieved partial hematologic remission. A complete cytogenetic response was induced in seven (8.8%) of 80 @entity1 treated with @entity3027 and two (2.5%) of 79 @entity1 treated with @entity1863 , and a partial cytogenetic response was 7.5% (6/80) and 2.5% (2/79), respectively. The difference in major (complete and partial) cytogenetic response between the two groups was significant (P = .046). At a median follow-up of 50 months, the predicted 5-year survival rate was 54% in the @entity3027 group and 32% in the @entity1863 group (P = .0290), and the predicted 5-year rate of remaining in chronic phase was 41% in the @entity3027 group and 29% in the @entity1863 group (P = .1165). As compared with the @entity1 with no cytogenetic response, the @entity1 with any cytogenetic response (complete, partial or minor) after the @entity3027 or @entity1863 treatment were significantly superior in the duration of chronic phase ( @entity3027 group; P = .0017, @entity1863 group; P = .0010) even after correction for the time to response using the landmark analysis. However, there was no significant difference in survival rate in the @entity3027 group (P = .1065). There was no significant difference in survival rate (P = .3923) and the duration of chronic phase (P = .6258) between the @entity3027 and the @entity1863 group in the @entity1 with a cytogenetic response (complete, partial or minor). These results demonstrate that @entity3027 treatment produces a significantly superior cytogenetic response and survival rate as compared with the @entity1863 treatment, and unexpectedly, that @entity1863 can also eliminate Philadelphia chromosome positive clone in a few @entity1 who showed prolonged survival rate and duration of chronic phase.
